CN104363913B - Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 - Google Patents
Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 Download PDFInfo
- Publication number
- CN104363913B CN104363913B CN201380017703.9A CN201380017703A CN104363913B CN 104363913 B CN104363913 B CN 104363913B CN 201380017703 A CN201380017703 A CN 201380017703A CN 104363913 B CN104363913 B CN 104363913B
- Authority
- CN
- China
- Prior art keywords
- cdk8
- cancer
- purposes
- drug
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LZRBJJFCGBZTFQ-SDQBBNPISA-N CC(C1C2)=NCNC1=CCC2/C=N\C Chemical compound CC(C1C2)=NCNC1=CCC2/C=N\C LZRBJJFCGBZTFQ-SDQBBNPISA-N 0.000 description 1
- AMESDSGVMHIJBO-UHFFFAOYSA-N CC([IH][I]1CCOCC1)=O Chemical compound CC([IH][I]1CCOCC1)=O AMESDSGVMHIJBO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261594023P | 2012-02-02 | 2012-02-02 | |
US61/594,023 | 2012-02-02 | ||
US61/594023 | 2012-02-02 | ||
US201261673419P | 2012-07-19 | 2012-07-19 | |
US61/673,419 | 2012-07-19 | ||
US61/673419 | 2012-07-19 | ||
PCT/US2013/024515 WO2013116786A1 (en) | 2012-02-02 | 2013-02-01 | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104363913A CN104363913A (zh) | 2015-02-18 |
CN104363913B true CN104363913B (zh) | 2018-08-21 |
Family
ID=47716178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380017703.9A Expired - Fee Related CN104363913B (zh) | 2012-02-02 | 2013-02-01 | Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 |
Country Status (16)
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6324380B2 (ja) | 2012-07-27 | 2018-05-16 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | S1p調節剤および/またはatx調節剤である化合物 |
EP2888232A1 (en) * | 2012-08-23 | 2015-07-01 | F. Hoffmann-La Roche AG | Novel phenyl-pyridine/pyrazine amides for the treatment of cancer |
CA2890108C (en) | 2012-11-01 | 2021-03-02 | University Of South Carolina | Method for treating prostate cancer |
WO2014134169A1 (en) * | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
MY180383A (en) | 2013-12-24 | 2020-11-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
EP3205645B1 (en) * | 2014-04-18 | 2019-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CA2959762A1 (en) * | 2014-06-10 | 2016-02-04 | University Of South Carolina | Methods and compositions for treatment of her-positive cancers |
US20210322651A1 (en) | 2014-12-18 | 2021-10-21 | Senex Biotechnology, Inc. | Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
WO2016182904A1 (en) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Targeted selection of patients for treatment with cortistatin derivatives |
EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
JP6977238B2 (ja) | 2015-11-03 | 2021-12-08 | エルユー ライセンス エービーLu License Ab | 低増殖性障害の治療のための化合物 |
WO2017091836A1 (en) * | 2015-11-25 | 2017-06-01 | University Of South Carolina | Enhancement of cytarabine activity by inhibiting cdk8/19 |
WO2017164230A1 (ja) * | 2016-03-23 | 2017-09-28 | 国立大学法人 岡山大学 | リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用 |
WO2018027082A1 (en) | 2016-08-03 | 2018-02-08 | The Broad Institute, Inc. | Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity |
EP3575297A4 (en) * | 2017-01-30 | 2021-07-28 | Kyoto University | NOVEL COMPOUND AND METHOD FOR PRODUCING REGULATORY T-CELLS |
WO2018151633A1 (ru) * | 2017-02-20 | 2018-08-23 | Закрытое Акционерное Общество "Биокад" | Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов |
WO2018156858A1 (en) * | 2017-02-23 | 2018-08-30 | University Of South Carolina | Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis |
EP3591040A4 (en) | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS |
RU2641001C1 (ru) * | 2017-04-03 | 2018-01-15 | Закрытое Акционерное Общество "Биокад" | Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция |
CA3058880A1 (en) * | 2017-04-03 | 2018-10-11 | Kyoto Pharmaceutical Industries, Ltd. | Novel cyclin-dependent kinase 8 and/or 19 inhibitor |
US11471477B2 (en) | 2017-09-18 | 2022-10-18 | Chan Zuckerberg Biohub, Inc. | Methods for treating triple-negative breast cancer |
WO2019068613A1 (en) | 2017-10-02 | 2019-04-11 | Boehringer Ingelheim International Gmbh | NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS |
RU2763347C2 (ru) * | 2018-03-01 | 2021-12-28 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
US11572369B2 (en) | 2019-02-01 | 2023-02-07 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
WO2022107877A1 (ja) | 2020-11-20 | 2022-05-27 | オリヅルセラピューティクス株式会社 | 成熟化剤 |
CN116829697A (zh) | 2021-02-09 | 2023-09-29 | 千纸鹤治疗公司 | 促熟剂 |
WO2022204534A1 (en) * | 2021-03-25 | 2022-09-29 | University Of South Carolina | Cdk8/19 inhibitors for the treatment of cytokine storm |
CA3234008A1 (en) | 2021-09-27 | 2023-03-30 | Kyoto University | Method for producing t cell |
CA3238860A1 (en) | 2021-11-24 | 2023-06-01 | Norihisa MIKAMI | Pharmaceutical composition for treating or preventing t cell-related disorders |
WO2023095801A1 (ja) | 2021-11-24 | 2023-06-01 | レグセル株式会社 | ヒト誘導性制御性t細胞およびその作製方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1276789A (zh) * | 1997-10-27 | 2000-12-13 | 阿古龙制药公司 | 4-氨基噻唑衍生物、其制备及其作为细胞周期蛋白依赖型激酶的抑制剂 |
CN1348455A (zh) * | 1999-04-21 | 2002-05-08 | 霍夫曼-拉罗奇有限公司 | 作为cdk2抑制剂的吡唑并苯并二氮䓬 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
US20040180848A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
US20040180844A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
JP2006522794A (ja) * | 2003-04-10 | 2006-10-05 | ファイザー株式会社 | Nr2b受容体拮抗物質としての二環系化合物 |
CA2652341A1 (en) * | 2006-05-15 | 2007-11-22 | Senex Biotechnology, Inc. | Identification of cdki pathway inhibitors |
US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
-
2013
- 2013-02-01 AU AU2013214783A patent/AU2013214783B2/en not_active Ceased
- 2013-02-01 EP EP18186536.1A patent/EP3431087A1/en not_active Withdrawn
- 2013-02-01 EA EA201791284A patent/EA032429B1/ru not_active IP Right Cessation
- 2013-02-01 BR BR112014019052A patent/BR112014019052A8/pt not_active Application Discontinuation
- 2013-02-01 SG SG11201404596UA patent/SG11201404596UA/en unknown
- 2013-02-01 UA UAA201409643A patent/UA117342C2/uk unknown
- 2013-02-01 EP EP13704538.1A patent/EP2809324B1/en not_active Not-in-force
- 2013-02-01 JP JP2014555805A patent/JP6193268B2/ja not_active Expired - Fee Related
- 2013-02-01 CN CN201380017703.9A patent/CN104363913B/zh not_active Expired - Fee Related
- 2013-02-01 WO PCT/US2013/024515 patent/WO2013116786A1/en active Application Filing
- 2013-02-01 MY MYPI2014002269A patent/MY165446A/en unknown
- 2013-02-01 EA EA201491399A patent/EA028595B1/ru not_active IP Right Cessation
- 2013-02-01 US US13/757,682 patent/US9321737B2/en active Active
- 2013-02-01 GE GEAP201313566A patent/GEP201706688B/en unknown
- 2013-02-01 KR KR1020147024672A patent/KR20150023223A/ko not_active Application Discontinuation
-
2014
- 2014-08-01 CL CL2014002062A patent/CL2014002062A1/es unknown
- 2014-08-18 PH PH12014501862A patent/PH12014501862A1/en unknown
- 2014-08-30 CO CO14191136A patent/CO7151516A2/es unknown
-
2016
- 2016-03-09 US US15/065,083 patent/US10993945B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1276789A (zh) * | 1997-10-27 | 2000-12-13 | 阿古龙制药公司 | 4-氨基噻唑衍生物、其制备及其作为细胞周期蛋白依赖型激酶的抑制剂 |
CN1348455A (zh) * | 1999-04-21 | 2002-05-08 | 霍夫曼-拉罗奇有限公司 | 作为cdk2抑制剂的吡唑并苯并二氮䓬 |
Also Published As
Publication number | Publication date |
---|---|
EA032429B1 (ru) | 2019-05-31 |
EP3431087A1 (en) | 2019-01-23 |
AU2013214783A1 (en) | 2014-08-28 |
EA201491399A1 (ru) | 2015-04-30 |
US10993945B2 (en) | 2021-05-04 |
US20140038958A1 (en) | 2014-02-06 |
US9321737B2 (en) | 2016-04-26 |
CO7151516A2 (es) | 2014-12-29 |
CN104363913A (zh) | 2015-02-18 |
EA028595B1 (ru) | 2017-12-29 |
US20170071942A1 (en) | 2017-03-16 |
KR20150023223A (ko) | 2015-03-05 |
CL2014002062A1 (es) | 2015-03-20 |
PH12014501862A1 (en) | 2014-11-24 |
GEP201706688B (en) | 2017-06-26 |
WO2013116786A1 (en) | 2013-08-08 |
BR112014019052A8 (pt) | 2017-07-11 |
EP2809324B1 (en) | 2018-08-01 |
EA201791284A1 (ru) | 2017-10-31 |
EP2809324A1 (en) | 2014-12-10 |
SG11201404596UA (en) | 2014-10-30 |
AU2013214783B2 (en) | 2017-07-06 |
MY165446A (en) | 2018-03-22 |
JP2015506376A (ja) | 2015-03-02 |
BR112014019052A2 (US07928230-20110419-C00014.png) | 2017-06-20 |
JP6193268B2 (ja) | 2017-09-06 |
UA117342C2 (uk) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104363913B (zh) | Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 | |
Liu et al. | Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin | |
CN106604719B (zh) | 用放射、氧化铈纳米颗粒、和化疗剂的组合治疗癌症 | |
US20070281040A1 (en) | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents | |
JP2020158507A6 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
CN105873440A (zh) | 适用于治疗癌症的用于抑制tie2激酶的方法 | |
CN105873592A (zh) | 用于治疗癌症的组合疗法 | |
CN106456635A (zh) | Mdm2抑制剂的间歇给药 | |
US11466273B2 (en) | Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer | |
AU2018352382B2 (en) | Compounds and methods for treating cancer | |
Song et al. | A novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells | |
CN106232115A (zh) | 用于治疗抗性的癌症的预防或治疗性组合物 | |
CN103298461A (zh) | 治疗肿瘤的方法 | |
Nakata et al. | S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU | |
Koutsougianni et al. | P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies? | |
US11389536B2 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
CN103002914A (zh) | 抑制mmset的组合物和方法 | |
TW201717926A (zh) | 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法 | |
CN105744958A (zh) | 新颖医药组成物及其用途 | |
CN114796503A (zh) | Kdm6a抑制剂和酪氨酸激酶抑制剂联合在制备抗肿瘤的药物中的用途 | |
Haokun | Oxaliplatin and Checkpoint Inhibitor Induces Immunogenic Cells Death and Promotes Therapeutic Efficacy in the Model of Murine Triple Positive Breast Cancer | |
CN111214659A (zh) | Cbx4抑制剂在制备食管鳞癌放射增敏剂中的应用 | |
Saranath et al. | Contemporary cancer therapy | |
Nassim | Radiosensitization of bladder cancer cells by the mTOR inhibitor, RAD001: a novel strategy for treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180821 Termination date: 20200201 |
|
CF01 | Termination of patent right due to non-payment of annual fee |